JP2013544290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544290A5 JP2013544290A5 JP2013542229A JP2013542229A JP2013544290A5 JP 2013544290 A5 JP2013544290 A5 JP 2013544290A5 JP 2013542229 A JP2013542229 A JP 2013542229A JP 2013542229 A JP2013542229 A JP 2013542229A JP 2013544290 A5 JP2013544290 A5 JP 2013544290A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- naltrexone
- bupropion
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 63
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 34
- 229960003086 naltrexone Drugs 0.000 claims 34
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 31
- 229960001058 bupropion Drugs 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 235000013305 food Nutrition 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 6
- 235000009200 high fat diet Nutrition 0.000 claims 4
- 235000012054 meals Nutrition 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 235000005911 diet Nutrition 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000016261 weight loss Diseases 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41939510P | 2010-12-03 | 2010-12-03 | |
| US61/419,395 | 2010-12-03 | ||
| PCT/US2011/063177 WO2012075459A1 (en) | 2010-12-03 | 2011-12-02 | Increasing drug bioavailability in naltrexone therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016177391A Division JP6456890B2 (ja) | 2010-12-03 | 2016-09-12 | ナルトレキソン療法における薬物バイオアベイラビリティの増加 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544290A JP2013544290A (ja) | 2013-12-12 |
| JP2013544290A5 true JP2013544290A5 (enExample) | 2015-01-29 |
| JP6008866B2 JP6008866B2 (ja) | 2016-10-19 |
Family
ID=46172304
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542229A Active JP6008866B2 (ja) | 2010-12-03 | 2011-12-02 | ナルトレキソン療法における薬物バイオアベイラビリティの増加 |
| JP2016177391A Active JP6456890B2 (ja) | 2010-12-03 | 2016-09-12 | ナルトレキソン療法における薬物バイオアベイラビリティの増加 |
| JP2018237245A Active JP7025319B2 (ja) | 2010-12-03 | 2018-12-19 | ナルトレキソン療法における薬物バイオアベイラビリティの増加 |
| JP2022019546A Pending JP2022060331A (ja) | 2010-12-03 | 2022-02-10 | ナルトレキソン療法における薬物バイオアベイラビリティの増加 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016177391A Active JP6456890B2 (ja) | 2010-12-03 | 2016-09-12 | ナルトレキソン療法における薬物バイオアベイラビリティの増加 |
| JP2018237245A Active JP7025319B2 (ja) | 2010-12-03 | 2018-12-19 | ナルトレキソン療法における薬物バイオアベイラビリティの増加 |
| JP2022019546A Pending JP2022060331A (ja) | 2010-12-03 | 2022-02-10 | ナルトレキソン療法における薬物バイオアベイラビリティの増加 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20130245056A1 (enExample) |
| EP (5) | EP4349369B1 (enExample) |
| JP (4) | JP6008866B2 (enExample) |
| KR (5) | KR102391511B1 (enExample) |
| CN (1) | CN103313711A (enExample) |
| AR (2) | AR093182A1 (enExample) |
| AU (2) | AU2011336304B2 (enExample) |
| BR (1) | BR112013013390A2 (enExample) |
| CA (2) | CA2819262C (enExample) |
| CL (1) | CL2013001564A1 (enExample) |
| CY (2) | CY1118968T1 (enExample) |
| DK (4) | DK4349369T3 (enExample) |
| ES (3) | ES2866879T3 (enExample) |
| FI (2) | FI3884947T3 (enExample) |
| HR (4) | HRP20251576T1 (enExample) |
| HU (3) | HUE053831T2 (enExample) |
| IL (4) | IL330443A (enExample) |
| LT (4) | LT3222280T (enExample) |
| MX (2) | MX384662B (enExample) |
| PL (4) | PL3222280T3 (enExample) |
| PT (4) | PT3222280T (enExample) |
| RS (4) | RS67527B1 (enExample) |
| RU (1) | RU2640561C2 (enExample) |
| SI (4) | SI3222280T1 (enExample) |
| SM (4) | SMT202100227T1 (enExample) |
| TW (1) | TWI618536B (enExample) |
| WO (1) | WO2012075459A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101167579B1 (ko) | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
| PT2135603E (pt) | 2005-11-22 | 2013-04-03 | Orexigen Therapeutics Inc | Composições e métodos para aumentar a sensibilidade à insulina |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| PT3222280T (pt) * | 2010-12-03 | 2021-04-22 | Nalpropion Pharmaceuticals Llc | Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona |
| PL4104824T3 (pl) | 2012-06-06 | 2025-11-12 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
| US20180015042A1 (en) * | 2015-02-07 | 2018-01-18 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition for the treatment of obesity |
| CA3083850A1 (en) * | 2017-03-28 | 2019-10-04 | LDN Pharma Limited | An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer |
| EP3482751A1 (en) | 2017-11-14 | 2019-05-15 | LDN Pharma Limited | Cancer treatment |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
| EP1772147A2 (en) * | 2003-03-17 | 2007-04-11 | Japan Tobacco, Inc. | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| KR101167579B1 (ko) | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
| JP2009502931A (ja) | 2005-07-27 | 2009-01-29 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少を促すための組成物 |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| PT2135603E (pt) | 2005-11-22 | 2013-04-03 | Orexigen Therapeutics Inc | Composições e métodos para aumentar a sensibilidade à insulina |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| JP2009517393A (ja) | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | 不安症の治療方法 |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| SI2484346T1 (sl) | 2006-06-19 | 2017-05-31 | Alpharma Pharmaceuticals Llc | Farmacevtski sestavki |
| KR101264789B1 (ko) | 2006-06-30 | 2013-05-15 | 엘지디스플레이 주식회사 | 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법 |
| CA2693992C (en) * | 2006-07-20 | 2017-01-31 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
| DE602007005402D1 (de) * | 2006-11-09 | 2010-04-29 | Orexigen Therapeutics Inc | Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht |
| WO2008060964A2 (en) * | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| KR20160065998A (ko) * | 2007-04-11 | 2016-06-09 | 바이오마린 파머수티컬 인크. | 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법 |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| US8318813B2 (en) * | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| PT3222280T (pt) * | 2010-12-03 | 2021-04-22 | Nalpropion Pharmaceuticals Llc | Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona |
-
2011
- 2011-12-02 PT PT171569858T patent/PT3222280T/pt unknown
- 2011-12-02 HR HRP20251576TT patent/HRP20251576T1/hr unknown
- 2011-12-02 BR BR112013013390A patent/BR112013013390A2/pt not_active Application Discontinuation
- 2011-12-02 SI SI201131967T patent/SI3222280T1/sl unknown
- 2011-12-02 HU HUE17156985A patent/HUE053831T2/hu unknown
- 2011-12-02 RS RS20251278A patent/RS67527B1/sr unknown
- 2011-12-02 FI FIEP21152314.7T patent/FI3884947T3/fi active
- 2011-12-02 SI SI201131199A patent/SI2646031T1/sl unknown
- 2011-12-02 PL PL17156985T patent/PL3222280T3/pl unknown
- 2011-12-02 MX MX2017013169A patent/MX384662B/es unknown
- 2011-12-02 MX MX2013006071A patent/MX356801B/es active IP Right Grant
- 2011-12-02 PL PL23209711.3T patent/PL4349369T3/pl unknown
- 2011-12-02 PT PT118451863T patent/PT2646031T/pt unknown
- 2011-12-02 EP EP23209711.3A patent/EP4349369B1/en active Active
- 2011-12-02 SM SM20210227T patent/SMT202100227T1/it unknown
- 2011-12-02 AR ARP110104512A patent/AR093182A1/es not_active Application Discontinuation
- 2011-12-02 ES ES17156985T patent/ES2866879T3/es active Active
- 2011-12-02 CA CA2819262A patent/CA2819262C/en active Active
- 2011-12-02 RU RU2013127423A patent/RU2640561C2/ru active
- 2011-12-02 KR KR1020217015625A patent/KR102391511B1/ko active Active
- 2011-12-02 EP EP25202419.5A patent/EP4696322A3/en active Pending
- 2011-12-02 PL PL11845186T patent/PL2646031T3/pl unknown
- 2011-12-02 AU AU2011336304A patent/AU2011336304B2/en active Active
- 2011-12-02 DK DK23209711.3T patent/DK4349369T3/da active
- 2011-12-02 JP JP2013542229A patent/JP6008866B2/ja active Active
- 2011-12-02 SM SM20170232T patent/SMT201700232T1/it unknown
- 2011-12-02 HR HRP20240115TT patent/HRP20240115T1/hr unknown
- 2011-12-02 SI SI201132141T patent/SI4349369T1/sl unknown
- 2011-12-02 LT LTEP17156985.8T patent/LT3222280T/lt unknown
- 2011-12-02 US US13/991,137 patent/US20130245056A1/en not_active Abandoned
- 2011-12-02 SM SM20240038T patent/SMT202400038T1/it unknown
- 2011-12-02 KR KR1020187016354A patent/KR101984500B1/ko active Active
- 2011-12-02 KR KR1020197014576A patent/KR102105857B1/ko active Active
- 2011-12-02 RS RS20210469A patent/RS62149B1/sr unknown
- 2011-12-02 SI SI201132102T patent/SI3884947T1/sl unknown
- 2011-12-02 DK DK11845186.3T patent/DK2646031T3/en active
- 2011-12-02 HU HUE11845186A patent/HUE034393T2/en unknown
- 2011-12-02 SM SM20250474T patent/SMT202500474T1/it unknown
- 2011-12-02 HU HUE21152314A patent/HUE065852T2/hu unknown
- 2011-12-02 KR KR1020207011510A patent/KR102258043B1/ko active Active
- 2011-12-02 CN CN2011800638854A patent/CN103313711A/zh active Pending
- 2011-12-02 IL IL330443A patent/IL330443A/en unknown
- 2011-12-02 PL PL21152314.7T patent/PL3884947T3/pl unknown
- 2011-12-02 WO PCT/US2011/063177 patent/WO2012075459A1/en not_active Ceased
- 2011-12-02 EP EP17156985.8A patent/EP3222280B1/en active Active
- 2011-12-02 DK DK21152314.7T patent/DK3884947T3/da active
- 2011-12-02 RS RS20170491A patent/RS56014B1/sr unknown
- 2011-12-02 HR HRP20170734TT patent/HRP20170734T1/hr unknown
- 2011-12-02 PT PT232097113T patent/PT4349369T/pt unknown
- 2011-12-02 LT LTEP23209711.3T patent/LT4349369T/lt unknown
- 2011-12-02 LT LTEP21152314.7T patent/LT3884947T/lt unknown
- 2011-12-02 DK DK17156985.8T patent/DK3222280T3/da active
- 2011-12-02 FI FIEP23209711.3T patent/FI4349369T3/fi active
- 2011-12-02 RS RS20240196A patent/RS65198B1/sr unknown
- 2011-12-02 TW TW100144442A patent/TWI618536B/zh active
- 2011-12-02 EP EP11845186.3A patent/EP2646031B9/en active Active
- 2011-12-02 ES ES23209711T patent/ES3056642T3/es active Active
- 2011-12-02 ES ES11845186.3T patent/ES2625527T3/es active Active
- 2011-12-02 EP EP21152314.7A patent/EP3884947B1/en active Active
- 2011-12-02 KR KR1020137017317A patent/KR20140035320A/ko not_active Ceased
- 2011-12-02 LT LTEP11845186.3T patent/LT2646031T/lt unknown
- 2011-12-02 CA CA3239386A patent/CA3239386A1/en active Pending
- 2011-12-02 PT PT211523147T patent/PT3884947T/pt unknown
-
2013
- 2013-05-23 IL IL226504A patent/IL226504B/en active IP Right Grant
- 2013-05-31 CL CL2013001564A patent/CL2013001564A1/es unknown
-
2016
- 2016-09-12 JP JP2016177391A patent/JP6456890B2/ja active Active
-
2017
- 2017-05-18 CY CY20171100524T patent/CY1118968T1/el unknown
- 2017-06-26 AU AU2017204309A patent/AU2017204309A1/en not_active Abandoned
-
2018
- 2018-12-19 JP JP2018237245A patent/JP7025319B2/ja active Active
-
2019
- 2019-11-21 IL IL270841A patent/IL270841A/en unknown
-
2020
- 2020-12-21 IL IL279626A patent/IL279626A/en unknown
-
2021
- 2021-04-19 HR HRP20210618TT patent/HRP20210618T1/hr unknown
- 2021-04-19 CY CY20211100340T patent/CY1124331T1/el unknown
- 2021-12-23 AR ARP210103655A patent/AR124500A2/es unknown
-
2022
- 2022-02-10 JP JP2022019546A patent/JP2022060331A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210618T1 (hr) | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom | |
| JP2010525050A5 (enExample) | ||
| JP2006504795A5 (enExample) | ||
| JP2010513320A (ja) | ピルフェニドン治療を患者に提供する方法 | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| RU2009142937A (ru) | Тапентадол для лечения в связи с остеоартрозом | |
| JP2013516493A5 (enExample) | ||
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| JP2007238598A5 (enExample) | ||
| US20080248015A1 (en) | Methods and kits for co-administration of nutritional supplements | |
| AU2010315561B2 (en) | Treatment of sunburn using analgesics and antihistamines | |
| WO2006040779A3 (en) | Controlled release gastric floating matrix formulation containing imatinib | |
| US20150110865A1 (en) | Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment | |
| CN103919774A (zh) | 去亚甲基小檗碱在制备降血脂药物中的应用 | |
| JP6481911B2 (ja) | 老化保護剤の可変投与量の終生服用、又はホルミシス事後適応向上用のデバイス | |
| JP2020512408A5 (enExample) | ||
| JP2012046484A5 (enExample) | ||
| US11213059B2 (en) | Nutritional formulations and kits for bariatric individuals | |
| JP2017530142A5 (enExample) | ||
| JP2017515858A5 (enExample) | ||
| EP1949900A3 (en) | Controlled release solid formulation for oral administration as single dose sachet and method of preparation thereof | |
| JP6143215B2 (ja) | 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤 | |
| JP6281919B2 (ja) | 高脂肪食への嗜好性を軽減させるための医薬組成物、飲食品組成物または飲食品添加剤 | |
| Data | Product Update | |
| TH1601004462A (th) | สารยับยั้งโปรตีนการถ่ายโอนโคเลสเทริล เอสเทอร์ (cetp) และองค์ประกอบเภสัช ที่ประกอบด้วยสารยับยั้งดังกล่าว สำหรับการใช้งานในการรักษาหรือป้องกันของโรคหัวใจร่วมหลอดเลือด |